Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).
Adolescent
Adult
Aged
Aged, 80 and over
Brain Neoplasms
/ diagnosis
Clinical Decision-Making
Combined Modality Therapy
Disease Management
Female
Humans
Karnofsky Performance Status
Male
Middle Aged
Neoplasm Grading
/ methods
Prognosis
Sarcoma
/ pathology
Severity of Illness Index
Treatment Outcome
Young Adult
Brain metastasis
Prognostic index
Sarcoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Feb 2020
12 Feb 2020
Historique:
received:
17
03
2019
accepted:
16
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases. We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index. The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a sub-group of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status. The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decision-making and outcomes research.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases.
METHODS
METHODS
We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index.
RESULTS
RESULTS
The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a sub-group of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status.
CONCLUSIONS
CONCLUSIONS
The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decision-making and outcomes research.
Identifiants
pubmed: 32050939
doi: 10.1186/s12885-020-6548-6
pii: 10.1186/s12885-020-6548-6
pmc: PMC7014599
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Subventions
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States
Références
JAMA Oncol. 2017 Jun 1;3(6):827-831
pubmed: 27892978
Eur J Cancer. 1980 Nov;16(11):1503-7
pubmed: 7227425
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
J Neurooncol. 2013 May;112(3):467-72
pubmed: 23462853
Cancer. 2001 Feb 1;91(3):585-91
pubmed: 11169942
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
Oncologist. 2018 Aug;23(8):948-955
pubmed: 29934413
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):218-24
pubmed: 15337559
Surg Neurol. 1998 Apr;49(4):441-4
pubmed: 9537665
Hum Pathol. 1993 Sep;24(9):1030-4
pubmed: 8253458
Oncogene. 2001 Jan 4;20(1):48-57
pubmed: 11244503
Cancer. 1988 Feb 1;61(3):593-601
pubmed: 3276383
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
pubmed: 19942357
Cancer. 1980 Jan 15;45(2):377-80
pubmed: 6243247
Cancer. 2002 May 15;94(10):2706-11
pubmed: 12173340
Rev Med Brux. 2003 Oct;24(5):408-15
pubmed: 14650317
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):510-4
pubmed: 17931798
J Neurosurg. 2009 Jan;110(1):181-6
pubmed: 18834268
Radiology. 1971 Apr;99(1):109-15
pubmed: 5548662
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
pubmed: 9128946
J Neurooncol. 2010 Jul;98(3):373-7
pubmed: 20039192
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816
pubmed: 29063850
Radiol Case Rep. 2016 Nov 23;12(1):113-119
pubmed: 28228892
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
pubmed: 10863071
Isr Med J. 1962 Jan-Feb;21:47-50
pubmed: 13872400
Cancer. 1989 Jan 1;63(1):1-13
pubmed: 2642727
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2111-7
pubmed: 21497451
Br J Cancer. 2004 Mar 22;90(6):1176-83
pubmed: 15026798
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1155-61
pubmed: 10725626
Sci Rep. 2017 Mar 27;7:45411
pubmed: 28345619
Eur J Cardiothorac Surg. 2014 Feb;45(2):386-8
pubmed: 23711464